2017 Results presentation

Operating income, growth figures, profitability and how our products have behaved.


Operating income, growth figures, profitability and how our products have behaved.

No votes yet
 
Related
ROVI reports operating revenue growth of 26% and EBITDA growth of 106%
Operating revenue increased by 26% to 381.3 million euros in 2019, mainly driven by the strength of the specialty pharmaceutical...
6 min
26/02/2020
ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union
ROVI filed its application for marketing authorisation for Doria® with the European health authorities, the European Medicines Agency (EMA...
2 min
31/01/2020